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There is a growing understanding that pathological genetic variation and 
environmental insults during sensitive periods in brain development have long-
term consequences in brain function, which range from learning disabilities to 
complex psychiatric disorders such as schizophrenia. Furthermore, recent 
experiments in animal models suggest that therapeutic interventions during 
sensitive periods, typically before the onset of clear neurological and behavioral 
symptoms, may prevent or ameliorate the development of specific pathologies. 
These studies suggest that understanding the dynamic nature of the 
pathophysiological mechanisms underlying psychiatric disorders is critical for the 
development of effective therapies. In this Perspective, I explore the emerging 
concept of developmental windows in psychiatric disorders, their relevance for 
understanding disease progression, and their potential for the design of new 
therapies. The limitations and caveats of early interventions in psychiatric 
disorders are also discussed in this context.   
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Psychiatric disorders are a major socio-economic burden, mostly because of the indirect 
costs derived from social support and unemployment1,2. Current treatments are based on 
symptoms, are not disease modifying, and have low response rates. For example, current 
treatments for schizophrenia only ameliorate psychotic symptoms in some patients and 
generally fail to improve cognition and other behavioral abnormalities3, and there are no 
effective pharmacological therapies for autism spectrum disorders (ASD) and related 
intellectual disabilities. Many factors contribute to the absence of effective treatments for 
psychiatric disorders, not least the lack of a clear understanding of their neurobiological 
substrates. In some cases, however, our knowledge of the underlying pathophysiology 
seems sufficient for the development of novel therapies, yet results are disappointing when 
new drugs are tested in adult patients4. 
Emerging data indicate that most neuropsychiatric disorders arise from the alteration 
of normal developmental trajectories, even if the age at which they are clinically diagnosed 
varies significantly, from toddlers in ASD to young adults in schizophrenia (Figure 1a). 
Transcriptomic analyses suggest that genes associated with psychiatric disorders are highly 
expressed during development5,6, and indeed many of the genes whose pathological 
variation confers susceptibility to psychiatric disorders play fundamental roles in brain 
development7-9. In addition, environmental risk factors such as hypoxia and maternal 
infection are early-life events10. Moreover, since neuronal circuits continue to exhibit 
robust plasticity –that is to say, remain able to reorganize in response to experience– well 
into adulthood11,12, the pathological organization of brain circuits in adult patients is 
probably the result of multiple homeostatic (compensatory) mechanisms operating over a 
protracted period. 
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Given the importance of developmental trajectories in mental illness, an emerging idea 
is that therapeutical intervention may impact brain function differently depending on the 
stage of the disorder, and that treatment in the adult brain might be less effective than at 
earlier stages13,14. Although development is a continuous process, the brain seems to be 
particularly vulnerable to insults (genetic and environmental) around specific sensitive 
periods in which changes in brain structure have long-lasting impact over the lifespan11. 
The existence of these critical windows in brain development suggests that early 
interventions might be necessary to overcome subsequent deficits, which are secondary to 
earlier perturbations. 
This Perspective explores the dynamic nature of the pathophysiological mechanisms 
underlying psychiatric disorders, with an emphasis on the developmental milestones that 
may critically influence disease progression and so the design of new therapies. While the 
article focuses on schizophrenia as an example of a psychiatric disorder that may benefit 
from early interventions, attention is also paid to syndromic neurodevelopmental disorders 
for which experimental therapeutics are being developed based on our current mechanistic 
understanding of these disorders.  Finally, the limitations and caveats of therapeutics 
interventions in the context of development are also outlined. 
Developmental milestones in the assembly of neural circuits 
Brain development spans over two decades in humans, from embryonic patterning to 
synaptic pruning in adolescence15 (Figure 1b). Several developmental milestones that are 
essential for the assembly and fine-tuning of neural circuits characterize this protracted 
period. Developmental milestones are sensitive time windows of particular transcendence 
for brain development because they have a long-lasting influence in the organization of 
brain circuits. For example, abnormal visual experience during a relatively narrow time 
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window in early development dramatically changes cortical circuits processing vision and 
has a major impact on visual ability16, whereas transient blindness in adulthood has much 
less severe functional consequences. It is therefore conceivable that even the most subtle 
variation in the organization of brain circuits during these sensitive time windows 
contributes to functional alterations that persist throughout life, as shown in animal 
studies17. These critical developmental windows exist for different brain regions, including 
those linked to high-order functions such as language and executive planning18,19 (Figure 
2). Consequently, anatomical and functional changes during these periods –due to gene 
variation or environmental pressure– are a major source of inter-individual variability in 
brain organization, which in extreme cases is pathogenic. 
Increasing evidence suggests that variation in the assembly and dynamic maintenance 
of specific neural circuits, primarily in the cerebral cortex and subcortical structures such 
as the basal ganglia and the amygdala, are at the core of psychiatric disease20-23 . The most 
sensitive time windows for vulnerability in the assembly of these neural circuits stretch 
from perinatal stages to adolescence. During this period, normal developmental 
progression is linked to the maturation of specific populations of cells. For example, 
oligodendrocytes are responsible for myelination in the CNS, and so defects in the 
maturation of these cells eventually impact long-range connectivity in the brain. In 
addition, although other populations of cells may have important functions at specific 
developmental windows, growing evidence suggest that neurons that use ɣ-aminobutyric 
acid (GABA) as their main neurotransmitter (also known as GABAergic neurons) play 
critical roles in the assembly of neuronal circuits at several consecutive stages (Figure 3), 
which may explain their prominent involvement in psychiatric disease24.  
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GABA may be an inhibitory or excitatory neurotransmitter depending on the 
intracellular concentration of chloride ions present in the receiving cell. Studies in rodents 
and non-human primates have shown during embryonic and early postnatal development 
GABA depolarizes –excites– because the intracellular concentration of chloride in the 
postsynaptic targets is higher than in the extracellular space25. During this period, GABA-
induced currents are the main source of depolarization and are critical for the generation of 
synchronized patterns of activity that characterize developing networks26. Early 
synchronous events are thought to play a fundamental role in the maturation of neuronal 
circuits27,28. 
 Shortly before delivery a reduction in the intracellular chloride concentration of 
neurons induced by oxytocin leads to a transitory excitatory-to-inhibitory switch of GABA 
actions29. This is thought to increase the resistance of neurons to hypoxia and ischemic 
damage during delivery. Delivery is associated with high risks to the fetal brain and 
preterm babies have a much higher incidence of neurological and cognitive impairments30. 
The perinatal period therefore represents one of the first developmental milestones in the 
assembly of cortical circuits31.  
At the end of the first postnatal week in the mouse there is a definitive switch of 
GABAergic signals from excitatory to inhibitory due to a progressive decrease in the 
expression of the ion co-transporter NKCC1 (Sodium/Potassium-Chloride Co-transporter 
1), which imports chloride, and a parallel increase in the expression of KCC2 (Potassium-
Chloride Co-transporter 2), which exports chloride25. The shift of GABA from excitatory 
to inhibitory corresponds with a sharp decrease in the correlated firing of cortical 
neurons32. This is an emerging property of mature cortices, in which information is 
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massively distributed across neurons and only small sets of neurons respond to any given 
stimulus. Thus, this is another crucial milestone in brain development. 
The desynchronization of spontaneous network activity coincides temporally with the 
increasing influence of sensory experience, through which external signals begin to shape 
synaptic connectivity by outcompeting internally generated activity33. During a period of 
time that varies according to the lifespan of species and the sensory modality, neuronal 
circuits are particularly receptive to different types of perceptual experience, from vision to 
fear34. These sensitive windows are known as critical periods35, and constitute another 
major milestone in the development of brain circuits. Because different brain areas process 
distinct types of information, critical periods are very diverse: some are linked to primary 
functions, such as vision, others to more complex tasks that involve cognitive experience, 
such as language acquisition or specific social behaviors. In any case, activity-dependent 
changes in brain circuits induced during a critical period have long lasting effects in brain 
function. In the mouse visual system, for example, critical period plasticity drives 
binocular matching, the process through which binocular neurons in the visual cortex 
(those that respond to information from both retinas) match their orientation preference36. 
It is conceivable that many unique features of neural computations are similarly 
established during critical periods across different brain areas and are important for 
disease.  
The onset and length of critical periods are strongly influenced by the maturation of 
GABAergic interneurons. In mice, genetic loss of GABAergic function and sensory 
deprivation delays plasticity, whereas GABAA receptor agonists such as benzodiazepines 
can trigger precocious onset of the critical period37. Fast-spiking interneurons expressing 
the calcium binding protein parvalbumin (PV+) are the main modulators of critical period 
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plasticity (Figure 4). These cells provide very strong inhibition to pyramidal cells38, and so 
their maturation rapidly restricts the influence of sensory experience in pyramidal cells and 
leads to the closure of critical period plasticity. In addition, the maturation of PV+ 
interneurons is crucial for the development of oscillatory activity across the neocortex and 
hippocampus. Fast-spiking PV+ interneurons synchronize local assemblies of pyramidal 
cells in the gamma frequency, which contributes to the emergence of functional 
interactions between the hippocampus and the prefrontal cortex39. 
In sum, the development of neural circuits in the cerebral cortex and associated 
subcortical structures is characterized by a number of developmental milestones that have 
long-lasting effect in the brain function. In the following sections, this conceptual 
framework will be used to illustrate how understanding of critical developmental time 
windows and homeostatic mechanisms that operate in different psychiatric conditions may 
inform about the appropriate timing of therapeutic interventions. 
Neurodevelopment and disease-modifying strategies in schizophrenia 
Schizophrenia is a chronic disorder characterized by a constellation of very diverse 
symptoms that affects approximately 1% of the population worldwide. Current treatments 
with antipsychotics are relatively effective in the management of psychotic symptoms 
(delusions, hallucinations, bizarre thoughts, paranoia), but they have modest impact upon 
negative symptoms (decreased expression, avolition)40, and fail to improve cognitive 
deficits, which are directly linked to poor real-world function41.  
Although schizophrenia is usually diagnosed in young adults at the time of the first 
episode of psychosis, our current understanding of its genetic and environmental causes 
links this disorder with abnormal neurodevelopment42,43. According to this view, psychosis 
is not the onset of the disorder, but rather a prominent consequence of a developmental 
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path toward schizophrenia that can be perhaps prevented through early intervention44. The 
notion that schizophrenia pathology worsen over time is supported by studies that suggest 
that long-term morbidity increases in the absence of any treatment45,46. This observation 
strongly reinforces the need for early interventions before pathological defects cascade into 
an irreversible state.  
The pathophysiology of schizophrenia remains poorly understood, but two of the most 
robust and replicated clinical findings are the elevated presynaptic dopamine function in 
the striatum47 and the existence of neuroanatomical and electrophysiological alterations in 
the medial temporal lobe, including the hippocampus, and in different areas of the 
prefrontal cortex48. In addition, several lines of evidence suggest that disruption of PV+ 
fast spiking interneurons is a core feature of schizophrenia49. For instance, the levels of one 
of the enzymes that contributes to the synthesis of GABA, GAD67, are consistently lower 
in the cortex of subjects with schizophrenia, and these defects are more prominent in PV+ 
interneurons 49. Moreover, the expression of several GABA receptors and markers of 
inhibitory synapses are also altered in schizophrenia50. Interestingly, some of these deficits 
are already present –albeit in a less pronounced manner– in individuals at ultra-high risk 
for psychosis. These patients have attenuated psychotic symptoms, and about 30% of them 
will develop a psychotic disorder within three years of their first clinical assesment51. 
Longitudinal imaging studies in humans have shown that levels of striatal dopamine 
increases progressively as subjects make the transition from high-risk to psychosis52. 
Similarly, small anatomical differences have been found in the medial temporal and frontal 
lobes of individuals prior to psychosis53, and cognitive impairment is already evident 
during adolescence in individuals that will subsequently develop schizophrenia54. Based on 
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these observations, disease-modifying strategies currently focus on identifying appropriate 
targets for treatment prior to the onset of psychosis.  
Several studies have exploited animal models to determine whether experimental 
treatments in juvenile mice can prevent schizophrenia-like phenotypes in adults (Table 1). 
One important limiting factor for this approach is that schizophrenia lacks clear monogenic 
syndromes that can be modeled in animals. For this reason, alternative experimental 
models have been generated that reproduce some of the symptoms observed in 
schizophrenia13. These are primarily based on pharmacological lesions of the developing 
hippocampus, such as the prenatal exposure to methylazoxymethanol acetate (MAM) and 
the neonatal ventral hippocampal lesion (NVHL) models55,56. Both models reproduce some 
of the defects observed in schizophrenia, including functional deficits in PV+ fast spiking 
interneurons. In addition, mice carrying mutations in a handful of genes reproduce 
neuroanatomical, functional and behavioral deficits observed in schizophrenia57, and stem 
cell-based models are beginning to be used for characterizing cellular defects linked to 
pathological gene variation58-60. The prominent differences that exist between rodents and 
humans in social cognition and communication have also led to the exploration of non-
human primate models for research in psychiatric disorders61. 
Since antipsychotics act on central dopamine receptors3, one possible strategy for 
prevention or course alteration in individuals at risk of schizophrenia is the use of 
antipsychotics on individuals at ultra-high risk for psychosis. This idea is supported by 
studies in the NVHL model for schizophrenia, in which administration of antipsychotics 
during adolescence diminishes schizophrenia-like phenotypes in adults62. However, clinical 
trials have failed so far to provide clear evidence that antipsychotics can prevent 
conversion to schizophrenia in at-risk individuals63. One possible explanation for this 
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failure could be that by the time presynaptic dopamine function is abnormally increased, 
several other changes have occurred that limit prevention.  Indeed, since dopamine is 
already elevated in some patients when they first seek help52, it is conceivable that striatal 
dopamine changes are secondary to other defects and preventive treatments should aim for 
an earlier developmental window for course alteration. Consistent with this idea, 
abnormally elevated excitation in cortical pyramidal neurons may lead to striatal 
hyperdopaminergia in mice64, and studies in the MAM model have shown that the changes 
in dopaminergic neurons might be secondary to the disruption of cortical circuits56.  
In humans, psychosis has also been associated with increased hippocampal glutamate 
levels65,66, although it is worth noting that changes in cortical glutamate levels may vary 
with the age and treatment history of the patients67. Mechanistically, increased activity of 
pyramidal cells might be a consequence of abnormal interneuron function, as previously 
shown in a genetic mouse model for schizophrenia68, and multiple lines of evidence 
suggest that interneuron function is disrupted in schizophrenia49. While additional studies 
are required to demonstrate that dysfunction in PV+ fast spiking interneurons precedes 
other defects in schizophrenia, deficits in gamma oscillations (a type of fast oscillatory 
activity that requires the function of PV+ fast spiking interneurons) has been reported in 
first episode schizophrenia patients69,70. It would be important to establish how early in the 
disease process GABAergic interneurons become compromised, as this will inform –based 
on their prominent role in cortical circuit assembly– about other possible alterations that 
might occur downstream of their altered function. At any rate, these studies suggest that 
restoring the balance between cortical pyramidal cells and interneurons in early phases of 
the disorder may prevent the onset of psychosis.  
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In addition to a possible link with striatal hyperdopaminergia, studies in animal 
models have shown that developmental disruption of PV+ fast spiking interneurons causes 
other phenotypes that are characteristic of schizophrenia, including abnormal gamma 
oscillations and long-range synchrony defects between the hippocampus and the prefrontal 
cortex68. In humans, normal gamma rhythms and hippocampal-prefrontal synchrony are 
critical for multiple cognitive tasks that are disrupted in schizophrenia28,39, and so several 
strategies have been devised to stimulate the function of fast spiking interneuron in 
schizophrenia. These include the use of GABAA-α2 agonists and inhibitors for the Na-K-
Cl cotransporter NKCC1, as in ASD (see below). While the results of these studies in adult 
patients are not encouraging13, it remains to be established whether normalization of 
GABAergic function well in advance to the onset of psychosis might lead to better 
outcomes. This approach is supported by the idea that GABAergic interneurons play 
fundamental roles in the establishment of neural circuits, as explained above. Consistent 
with this view, reducing stress sensitivity in juvenile MAM-treated rats with 
benzodiazepines prevents the abnormal increase in the activity of dopaminergic neurons 
and reduces hyperlocomotion in adult rats71. Since benzodiazepines enhance the effect of 
GABA on GABAA receptors72, these experiments reinforce the view that early modulation 
of cortical inhibitory circuits might contribute to prevent the onset of psychosis in 
schizophrenia. 
Considering the clinical heterogeneity of schizophrenia, it seems likely that different 
pathophysiological mechanisms may operate in different groups of patients, even if the 
final behavioral and functional deficits are relatively conserved. Despite limitations in the 
understanding of schizophrenia genetics, several animal models have been generated that 
are beginning to shed light into the heterogeneous mechanisms that lead to schizophrenia. 
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Some of the most relevant genetic models to date are based on relatively rare syndromic 
versions of schizophrenia, but it is expected that new mouse models will soon follow the 
recent discoveries derived from genome-wide association studies73. For example, 
Df(16)A+/- mice are a model of DiGeorge syndrome, caused by a microdeletion (22q11.2) 
that accounts for a small percentage of schizophrenia cases74. Human 22q carriers have 
cognitive deficits75, and approximately one third of them develop schizophrenia76. 
Df(16)A+/- mice have prominent working memory deficits that are likely caused by 
impaired functional connectivity between the hippocampus and the prefrontal cortex77. The 
observation that haploinsufficiency of Zdhhc8, one of the genes in the 22q11.2 
microdeletion, might be responsible for the developmental disconnection between the 
hippocampus and the prefrontal cortex found in Df(16)A+/- mice has led to the 
identification of a new possible target for the treatment of DiGeorge syndrome. In 
Zdhhc8+/- mice, abnormally high levels of Gsk3β during development seem to contribute to 
axonal branching deficits in these mice78. Consistent with this hypothesis, inhibition of 
Gsk3β signaling in juvenile Df(16)A+/- mice rescues the functional connectivity between 
the hippocampus and prefrontal cortex and improves working memory in these mice79. 
This work reinforces the notion that developmental interventions might be potentially 
transformative in the treatment of schizophrenia. 
Another indication of the potential of early intervention therapies for schizophrenia is 
the link between oxidative stress and schizophrenia. Decreased brain levels of glutathione 
(GSH), the most abundant endogenous antioxidant, have been observed in schizophrenia80, 
and mouse mutants with GSH deficits or mitochondrial dysfunction show morphological, 
electrophysiological and behavioral anomalies that are common to schizophrenia81. 
Treatment of adolescent NVHL rats with the GSH precursor N-acetylcysteine prevents the 
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electrophysiological and behavioral deficits that are characteristic of this animal model82. 
Interestingly, redox dysregulation severely impacts the development of PV+ fast spiking 
interneurons81,83 and, consequently, also disrupts critical period plasticity in the developing 
cortex of mice84. Consistent with this, results from a small-scale trial suggest that N-
acetylcysteine (in addition to antipsychotics) may improve negative symptoms and social 
functioning in schizophrenia patients85. Although larger clinical trials would be required to 
confirm its efficacy, these studies seem to support the idea that redox dysregulation 
contributes to aberrant developmental trajectories in schizophrenia and that early 
correction of this imbalance may have therapeutic potential86. 
Several lines of evidence suggest that non-pharmacological interventions may increase 
their therapeutical value when applied early. For example, environmental enrichment 
(enhancing the development of sensorimotor and cognitive functions through improved 
housing conditions stimulations) in juvenile mice reduces the impact of pharmacological 
manipulations that cause cognitive deficits in adult mice87. Similarly, cognitive training 
during adolescence improves cognitive function mediated by the prefrontal cortex and the 
hippocampus in adult NVHL rats88. Although the neural mechanisms underlying these 
effects remain unclear, these studies reinforced the notion that early interventions may 
have a profound impact in the reorganization of brain circuits affected in schizophrenia. 
Lessons from syndromic disorders with childhood diagnosis 
Syndromic neurodevelopmental disorders that are diagnosed early in life represent a small 
fraction of psychiatric disease diagnoses, but insights from their study may allow the 
identification of therapeutic targets and critical windows that might also be relevant for 
idiopathic disorders. While frequently grouped under the large umbrella of ASD and 
related intellectual disabilities, many of these disorders follow divergent trajectories that 
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suggest that treatments should be tailored accordingly. The differences in disease 
progression, which correlate with distinct temporal dynamics in the experience-dependent 
maturation of neural circuits, are very prominent in two of the best-characterized 
syndromic neurodevelopmental disorders, Fragile X syndrome and Rett syndrome. 
Fragile X syndrome 
Fragile X syndrome (FXS) is an X-linked neurodevelopmental disorder associated with 
autism, learning disabilities, abnormal attention, hyperactive and impulsive behaviors, and 
epilepsy, affecting approximately 1 in 4,000 males89. Females are typically less affected 
and their clinical presentation is more variable, as they still carry one active copy of the 
affected gene. The disorder is primarily caused by expansion of a CGG triplet repeat in the 
5′ untranslated region of the fragile X mental retardation 1 (FMR1) gene that cause a 
reduction of the FMR1 protein, although several other mutations in FMR1 have been 
described90. FMR1 is an RNA-binding protein that regulates neuronal protein synthesis91. 
Studies in animal models have shown that FMR1 regulates synaptic plasticity by inhibiting 
protein synthesis downstream of group 1 metabotropic glutamate receptors (mGluR), 
which is responsible for the stable internalization of AMPA receptors required for long-
term depression (LTD) 92. In the absence of FMR1, uncontrolled mGluR signaling leads to 
exacerbated LTD and deceleration of synapse maturation, thereby contributing to the 
cognitive impairment associated with FXS92. 
One of the aspects that the mGluR theory of FXS fails to capture comprehensively is 
the transient nature of many of the defects found in Fmr1 mutant mice. Delays in the 
developmental trajectories of motor, speech, and social skills are behavioral hallmarks of 
FXS93. Fmr1 mutant mice have a significant delay in the stabilization of dendritic spines 
and in the maturation of thalamocortical and corticocortical synapses94-98, defects 
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associated with a temporal shift in the critical period for sensory-induced plasticity across 
different cortical areas94,97,99-101. This suggests that Fmr1 is particularly important for the 
refinement of neuronal circuits during this developmental time window. 
In addition to developmental delay, FXS patients are characterized by a high incidence 
of hyperexcitable EEG patterns and cortically derived seizures102. Consistently, Fmr1 
mutant mice are highly susceptible to seizures103 and exhibit abnormally high cortical 
network synchrony during juvenile stages104. Hypersynchrony is due to a higher than 
normal proportion of active pyramidal cells, which are intrinsically more excitable and 
have increased firing rates104,105. While persistent mGluR5 activation has been shown to 
increase the excitability of pyramidal cells106, defects in GABAergic signaling may also 
contribute to the hyperexcitability observed in Fmr1 mutant mice107. In particular, there is a 
prominent delay in the normal excitatory to inhibitory switch of GABA during postnatal 
development due to abnormally high levels of NKCC1 beyond P10 in Fmr1 mutant 
mice108,109. In addition, widespread defects in GABAergic signaling across cortical and 
subcortical regions may also contribute to the abnormal hyperexcitability of juvenile Fmr1 
mutants107. 
Preclinical studies have primarily focused on mGluR5 signaling as potential targets for 
treatment in adult mice99,110-113. However, several drug development programs based on the 
inhibition of mGluR signaling for the treatment of FXS (Novartis and Seaside 
Therapeutics) were recently closed because efficacy studies in adolescents and adults 
showed no measurable benefits114,115. Similarly, treatment with GABAA and GABAB 
receptor modulators seems to control hyperexcitability in Fmr1 mutant mice, but similar 
approaches in human patients have failed to yield positive outcomes107,116. While the results 
of these studies may indicate that preclinical studies in mice are not directly translatable to 
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humans, an alternative interpretation is that the developmental window of intervention 
used in these trials might be desynchronized with the developmental timing of alterations 
in FXS patients. In that context, a recent clinical trial with bumetanide, a drug that inhibits 
NKCC1, has shown improved accuracy in facial emotional labeling and enhanced 
communication in a group of ASD children between the ages of 3 and 11 years117,118. 
Bumetanide has also been shown to prevent pathology in a genetic epilepsy mouse model 
when administered transiently during early postnatal development119. These results 
reinforce the view that treatment benefits may only be seen if started in early childhood. 
Rett syndrome 
 Recent work on another neurodevelopmental disorder illustrates the increasing recognition 
of developmental milestones for designing effective treatments. Rett Syndrome (RTT) is 
an X-linked neurodevelopmental disorder that is primarily caused by mutations in the gene 
coding for methyl CpG-binding protein 2 (MECP2). Most affected individuals are female 
heterozygotes who are somatic mosaics for normal and mutant MECP2120. The disease is 
characterized by seemingly normal postnatal development followed by a sudden 
deceleration in growth associated with progressive loss of acquired motor and language 
skills, stereotypic hand movements, muscle hypotonia, autonomic dysfunctions and severe 
cognitive impairment121. MECP2 is global transcriptional modulator and multifunctional 
mediator of protein interactions that is strongly expressed in the CNS at a time that 
correlates with neuronal maturation and synaptogenesis122. 
The consequences of MeCP2 dysfunction on neuronal networks have been extensively 
explored in mice lacking MeCP2 and those with a conditional hemizygous deletion, but the 
results vary considerably possibly due to differences in the age of the mice in the analysis 
(juvenile, young adults and adults) and the specific characteristics of each cortical 
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area123,124. Recent studies suggest that the abnormal activity of cortical circuits might be 
caused by the precocious development of GABAergic interneurons, a hypothesis that has 
been primarily tested in the visual cortex. In a pattern that resembles the relapse of RTT 
patients, vision acuity initially develops normally in Mecp2 mutants but regresses in young 
adult mice125. Loss of vision is preceded by the accelerated development of Parvalbumin-
expressing (PV+) fast-spiking basket cells that provide perisomatic inhibition to pyramidal 
cells125-127. Consistent with the observation that maturation of PV+ interneurons triggers the 
onset of the critical period128 (Figure 2), Mecp2 mutants have a precocious onset and 
closure of critical period plasticity125,126. Inhibitory function seems to normalize in young 
adult mice129, perhaps due to homeostatic compensations following long-term reduction of 
activity levels126, but the early alterations in neural networks cause long-term functional 
deficits125. 
The precocious window of critical period plasticity observed in Mecp2 mutant mice 
(which reduces the influence of visual experience on the developing cortex) can be rescued 
by reducing sensory inputs (dark-rearing), decreasing the activation of PV+ interneurons 
by pyramidal cells (NMDA receptor disruption) or reducing GABAergic 
neurotransmission (Gad67 reduction)125-127. These results indicate that MeCP2 function is 
required for experience-dependent synaptic remodeling during postnatal development and 
suggest possible pathways – and most importantly, timing – for therapeutical interventions. 
Preclinical studies have shown that disinhibition of pyramidal cells through low (sub-
anesthetic) doses of ketamine, an NMDAR antagonist that acts preferentially on PV+ 
interneurons reducing the excitatory drive onto these cells130, normalizes inhibitory 
connectivity, prevents the silencing of cortical circuits, and extends the lifespan of Mecp2 
mutants131. Ketamine treatment normalizes cortical activity in both young adults and adult 
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mice131,132, but it remains to be tested whether early and late treatments achieve similar 
results in restoring function. 
In summary, animal studies of neurodevelopmental disorders such as FXS and RTT 
reinforce the view that sensitive periods during early postnatal development are likely 
critical for the emergence of many of the deficits observed in these disorders. It should be 
noted that these conclusions seem at odd with work suggesting that behavioral deficits in 
mouse models FXS and RTT can be reverted in adulthood133. The most likely explanation 
for this apparent discrepancy is that the proteins involved in these disorders also play 
important functions in the mature brain133,134. Consequently, behavioral phenotypes are 
likely caused by both developmental and adult pathophysiology, and early interventions 
stand a better chance to restore the original deficits. 
Practical considerations and caveats of early intervention 
Early intervention in psychiatric disorders have practical considerations and limitations 
that are common to therapeutic approaches in adulthood, such as the difficulty in assessing 
the impact of treatments in non-syndromic conditions In particular, with regard to treating 
children and adolescents, attention should be given to the identification of target groups, 
the adverse effects of early treatments, the translational potential of rodent brain 
development studies, and ethical concerns.  
Since most risk factors to which at risk individuals are potentially exposed in early 
development only contribute minimally to non-syndromic neurodevelopmental disorders, 
assessing the benefits of early treatment is very difficult. For this reason, I recommend that 
the development of early interventions should initially focus on those with the highest 
relative risk for developing a psychiatric condition. This would include individuals 
carrying mutations associated with syndromic neurodevelopmental disorders such as 
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22q11 deletion syndrome, or individuals with a first-degree relative with a psychiatric 
condition135,136 or greatly vulnerable, such as extreme premature babies or adolescents at 
ultra-high risk for psychosis137,138. Even within these relatively constricted populations, 
additional biomarkers would be required to improve our ability to assess treatment success 
though much research is required before such biomarkers will be available. A universal 
genetic biomarker of the risk of transition to schizophrenia is not currently available, 
although studies are beginning to link specific gene variation with increased risk for 
transition to psychosis139. In addition, biochemical140,141, imaging52,142,143, and 
electrophysiological measurements144 may help segregating patients into higher- and 
lower-risk groups. However, since not every individual develops at exactly the same 
pace145, the developmental trajectory of specific measurements is probably more important 
for defining early risk than deficits at specific time points during development. For 
example, attention to eyes is progressively loss during a period of several months in 
children later diagnosed with ASD146, and it is likely that many biomarkers of 
schizophrenia and other psychiatric disorders that are diagnosed in young adults may have 
a similar longitudinal dimension. While this approach may increase our ability to stratify 
patient groups, the cost of the longitudinal assessment of ‘at risk’ populations should not 
be underestimated. 
There are several important considerations in relation to the safety of early 
interventions. First, while early intervention may prevent subsequent symptoms caused by 
the dynamic reorganization of developing circuits, the adverse effect of treatments may 
also cascade over time when targeted to children or adolescents13,14. For instance, weight 
gain caused by atypical antipsychotic drugs may have a more profound impact on child 
behavior than in adults147. Secondly, treatment in children and adolescents may trigger 
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unexpected side effects that are unique to these patient populations. As described above, 
many therapeutical interventions in ASD and schizophrenia aim to target inhibitory 
interneurons, and these treatments have minor secondary effects in healthy adults. In 
young rodents and primates, however, acute exposure to NMDA blockers and GABAA 
receptor agonists triggers widespread apoptotic death of neurons in the developing brain148-
150. If these drugs were to affect human brain development in a similar manner, the 
developmental window for this vulnerability may well extent for several years after birth. 
Thirdly, the clinical output of ‘at risk’ populations is not homogeneous. Individuals 
carrying 22q11 deletions may develop ASD, schizophrenia, depression or anxiety 
disorders, among other conditions151, and most individuals at ultra-high risk for psychosis 
transition to a psychiatric disorder other than schizophrenia, including major depressive 
disorder or bipolar disorder138. In the absence of additional markers for patient 
stratification, early treatments would need to take into consideration the diversity of 
behavioral outcomes that may arise from divergent developmental trajectories. 
As discussed above, studies in animal models for syndromic neurodevelopmental 
disorders such as FXS and RTT have substantially advanced our understanding of the 
pathophysiological mechanisms operating in these conditions. Yet, discoveries are not 
easily translatable to humans4. Although it is unlikely that the affected proteins play very 
different roles in rodents and humans, several studies have shown species-specific patterns 
of expression for some genes that play important roles in neurodevelopment, in particular 
in the organization of the cerebral cortex15. In addition, since the behavior of humans and 
rodents is highly divergent, animal model studies should shift their emphasis from 
behavioral analyses to the identification of more translatable circuit-based 
electrophysiological deficits61. Most notably, the vital cycle of rodents is very different 
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from humans. From the perspective of developmental trajectories, a four-week treatment in 
newborn mice would be equivalent to over a decade of life in children. However, receptor 
sensitization might have similar dynamics in both species, and so a four-week treatment 
may indeed have similar effects in rodents and humans from a pharmacological point of 
view. Addressing these questions would be critical for the design of clinical trials based on 
early interventions. 
Finally, developing new treatments for children and adolescents have important ethical 
and regulatory implications. Assessing efficacy and safety of newly developed compounds 
to treat neuropsychiatric diseases in adults seems counterproductive, as benefits might only 
be appreciated if individuals are treated as children or young adolescents. On the other 
hand, testing new pharmacological treatments in children may have unwanted 
consequences. Moreover, since we are currently unable to reliably predict pathological 
trajectories in ‘at risk’ populations and not everyone from these groups will go on to 
develop a psychiatric condition, treatment will impact the developmental trajectories of 
potentially healthy individuals. Finally, with the possibility of reliable biomarkers in the 
future, we may be able to improve ‘pre-symptomatic’ diagnosis. Another key ethical 
question is whether telling children about their ‘at risk’ status may harm them, and even 
increase their risk by exacerbating other risk factors, such as anxiety. 
Conclusions and outlook 
Recognizing the developmental context of neuropsychiatric disorders is giving new 
impetus to research in this field. Neural network dynamics are extremely complex and 
change dramatically with disease progression, as shown in animal model studies exploring 
the function of specific neural circuits at different stages. This is contributing to shift the 
emphasis of therapeutic approaches to neuropsychiatric disorders from symptomatic 
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treatment (typically in the adult) to course-alteration (ideally before the onset of main 
symptoms. 
Studies in animal models are also shifting from the analysis of behavioral deficits to 
the interrogation of neural circuit abnormalities61, which is proving more powerful for the 
identification of pathophysiological mechanisms. This approach has revealed that the 
developmental trajectories of relatively close clinical conditions may diverge substantially, 
even when they share common behavioral deficits. In the case of psychiatric disorders that 
are diagnose relatively late in life such as schizophrenia, a better understanding of the 
longitudinal time course of initial symptoms will be necessary for the successful 
implementation of early therapies. Finally, and perhaps most importantly, clinical trial 
design for neurodevelopmental disorders must begin considering appropriately how 
developmental timing and critical windows will impact prospective results. Lumping 
together children and adolescents in the same clinical trials with no consideration for the 
dynamic changes that operate during brain development may reduce the possibilities of 
identifying potentially successful treatments. Looking forward, our ability to develop 
disease-modifying interventions that are time-matched to the specific state of neural 
networks at any given stage of development may prove indispensable for the treatment of 
many psychiatric disorders. 
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Figure legends 
 
Figure 1.  Age of diagnosis for several neuropsychiatric disorders in relation to key 
processes in human neurodevelopment. (a) Most neuropsychiatric disorders have an age of 
onset in childhood or adolescence. Neurodevelopmental conditions in the autism spectrum 
disorders (ASD) can be diagnosed shortly after birth, typically before two years of age. 
Most impulse-control disorders (such as Attention deficit hyperactivity disorder, ADHD) 
and anxiety disorders (such as phobias) also begin in childhood, whereas schizophrenia 
and bipolar are typically diagnosed in late adolescence or early adulthood. Mood disorders 
have a protracted period of onset. Numbers inside the horizontal bars represent median age 
of diagnosis. Diagnostic age for autism varies greatly across countries. Adapted from Refs 
152,153. (b) The figure provides a timeline of human development during prenatal (in post 
conception weeks, pcw) and postnatal (in years) periods, in which the horizontal bars 
represent the approximate timing of key neurobiological processes and developmental 
milestones. The illustrations show gross anatomical features and relative size of the brain 
at different stages. See Ref. 15 and references therein for details about specific 
developmental events. 
 
Figure 2.  Brain regions affected in schizophrenia. Prefrontal cortex, hippocampus, basal 
ganglia, amygdala.  
 
Figure 3.  Milestones in the development of neural networks in the rodent neocortex. The 
figure provides a timeline of mouse development during prenatal (in post conception days, 
pcd) and postnatal (in postnatal days, pnd) periods, in which the horizontal bars represent 
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the approximate timing of key stages in the maturation of neural networks in the rodent 
neocortex. The scheme represents processes in the primary visual cortex. Some of the main 
processes involved with the assembly of neural networks are directly linked to the 
maturation of GABAergic interneurons, including the switch from excitatory to inhibitory 
GABA, the generation of transient (early network oscillation, ENO; giant depolarizing 
potentials, GDP) and mature (theta, gamma) oscillatory rhythms, and the critical period for 
ocular dominance (OD) plasticity. Adapted from Refs. 31,37,154. 
 
Figure 4.  Regulation of critical periods of plasticity by PV+ interneurons under the 
influence of sensory stimuli. 
 
